real-time news and commentary for investors
Friday, Aug 16
Cadence Pharmaceuticals slips on USPTO rejection of certain claims on Ofirmev
- Cadence Pharmaceuticals (CADX -4.6%) slips after the USPTO issued preliminary decision yesterday rejecting certain claims for one of two licensed patents underlying its Ofirmev injection, now part of a legal fight with Exela Pharma.
- In response, CADX notes that it's very common for the USPTO to reject some or all of the claims of a patent in an initial office action, and this is not a final decision, but just one step in the reexamination process, which can take many years to complete.
- The company doesn't expect the decision to have an adverse impact on the pending litigation against Exela.